June 2026 Research Update

This month added more consistent evidence that allogeneic hematopoietic stem cell transplantation (allo-HSCT, a donor stem cell transplant) can sometimes switch VEXAS off at its source by clearing the UBA1-mutated blood cell clone. In a multicenter comparison and a transplant-focused review, allo-HSCT was linked with higher rates of molecular remission (the mutation becoming undetectable) and more people coming off glucocorticoids than hypomethylating agents such as azacitidine. [1] [2]

In the multicenter retrospective cohort, the allo-HSCT group had molecular remission in all evaluable patients and more frequent glucocorticoid discontinuation than the hypomethylating agent group, with better adjusted overall survival reported. The same report also noted that stopping hypomethylating agents was common due to toxicity or lack of response, and deaths occurred in both groups during follow-up. [1]

A separate paper combined a detailed transplant case with a review of 45 transplanted patients and described durable control in many recipients, with inflammatory symptoms resolving in most. It also highlighted that transplant can involve serious complications such as graft-versus-host disease (GVHD), which in the reported case was managed with ruxolitinib. [2]

For patients, these studies mainly add clarity about which approach is more likely to eliminate the underlying mutated blood cell population: allo-HSCT more often led to the mutation becoming undetectable and to reduced reliance on steroids than hypomethylating agents in the reported data. This does not mean transplant is right for everyone, because it can bring major risks and the best timing and candidate selection are still not settled in the research. What became clearer this month is that clearing the UBA1 clone (molecular remission) is being measured more often, and it is a key way researchers are comparing long-term disease control across treatments. [1] [2]

This month, studies focused on making it easier to suspect VEXAS earlier and confirm it faster with genetic testing. One group built a simple clinical screening tool using five features that were more common in genetically confirmed VEXAS, and another group validated a rapid PCR-based lab test that can quickly detect the most common UBA1 mutations. Together, these studies point toward a two-step idea: recognize a typical pattern, then confirm it with targeted genetic testing when appropriate. [3] [4]

In the Chinese retrospective case-control study of men with unexplained systemic inflammation and blood abnormalities, VEXAS was more likely when disease began at an older age and included skin lesions, chondritis (inflamed cartilage such as the ear or nose), macrocytic anemia, and bone marrow vacuoles. A points-based tool using these five features showed good ability to separate VEXAS from non-VEXAS in that cohort and performed well in external validation sets from France and Spain. The same report also noted that skin problems often appeared early, which may matter when VEXAS is being considered among other inflammatory conditions. [3]

In a small prospective cohort, a rapid allele-specific real-time PCR test detected UBA1 codon 41 hotspot mutations in 5 of 6 people with high clinical suspicion and matched Sanger sequencing results exactly for those tested. The authors emphasized that this assay only targets three common codon 41 mutations, so a negative result would not rule out VEXAS if symptoms strongly fit and broader sequencing may still be needed. [4]

For patients and caregivers, these studies matter because delays in diagnosis are common, and VEXAS can look like other inflammatory diseases at first. The work this month suggests there are practical ways to narrow suspicion using a short list of clinical and blood or bone marrow features, and then to confirm many cases quickly with a focused genetic test that is available on standard PCR machines. What remains uncertain is how well these tools perform across all populations and across less common UBA1 mutations, since both studies were relatively small and one focused on men with a specific presentation. [3] [4]

This month’s case reports reinforced that VEXAS can present in very different ways and can respond differently to different approaches, ranging from targeted anti-inflammatory drugs to treatments aimed at replacing the blood-forming system. Some reports described strong improvement or remission with specific medicines, while others showed that long-term control sometimes required stem cell transplantation. Case reports cannot predict what will happen for most people, but they help map the edges of what VEXAS can look like and what kinds of responses have been observed. [5] [6] [7] [8] [9] [10]

Two single-patient reports described remission without transplant using medicine-based strategies, but in very different circumstances. One man in his seventies improved rapidly after baricitinib (a JAK inhibitor) was added when steroid tapering failed, reaching remission within 3 months with no recurrence reported at 6 months. Another report described an 81-year-old man who entered drug-free remission after methotrexate caused significant bone marrow suppression, alongside tapering off prednisone, with the UBA1 mutation becoming undetectable in follow-up testing. [5] [6]

Several reports emphasized the blood-clone nature of VEXAS by tracking genetics over time and showing how transplant can eliminate mutated clones. One case followed the rise and fall of a UBA1-mutated clone and a trisomy 8 subclone; azacitidine reduced both but did not remove them, while cord blood transplantation cleared them and was followed by sustained remission. Another case described VEXAS presenting as both artery and vein inflammation, with remission reported after allo-HSCT despite severe low blood counts before transplant. [7] [8]

Case reports also broadened who and what to consider when VEXAS is suspected. One report documented VEXAS in an 84-year-old woman with Turner syndrome (constitutional monosomy X), showing it is not limited to older men when X chromosome loss is present. Another described a man whose early skin biopsy showed eosinophils (a type of white blood cell) and who did not have clear blood abnormalities at first, with macrocytosis and anemia developing later; a literature review in that paper suggested eosinophils appear in only a minority of reported VEXAS skin biopsies. [9] [10]

For patients, these reports mainly add real-world examples of how varied VEXAS can be at the start and over time, including skin-first presentations, vessel inflammation that involves veins, and the possibility of VEXAS in some women with X chromosome loss. They also show that researchers are paying close attention to whether the UBA1 mutation level changes with treatment, because that may help explain why symptoms improve or return in some situations. What remains uncertain is how often these individual experiences apply to others, since each report describes a single person and often includes unusual circumstances like coexisting chromosome changes or medication-related bone marrow suppression. [5] [6] [7] [8] [9] [10]